目的 观察抗原负载的树突状细胞(dendritic cell, DC)与细胞因子诱导的杀伤细胞(cytokine induced killer, CIK)共培养 (Ag-DC-CIK)细胞对晚期视网膜母细胞瘤(retinoblastoma, RB)的疗效及其安全性。方法 收集武警总医院2011-01至2014-01确诊为晚期RB的26例患儿资料,其中13例采用Ag-DC-CIK细胞回输联合常规治疗方案治疗(联合组);其余13例仅采用常规治疗方案治疗(常规组)。对比分析两组患儿资料,观察Ag-DC-CIK细胞治疗的疗效及安全性。结果 联合组患儿共接受67疗程134次Ag-DC-CIK细胞治疗。联合组2例D期患儿均获保眼机会,初诊时无手术机会的4例眼外期、远处转移期患儿2例获手术机会;常规组2例D期患儿均未获保眼机会,初诊时无手术机会的4例眼外期、远处转移期患儿仅1例获手术机会。联合组治疗后外周血中CD3+、CD4+ 、CD4+ /CD8+ 、CD3+ CD56+T淋巴细胞比例较治疗前明显升高(均P<0.05),CD8+T淋巴细胞比例较治疗前明显降低(P<0.05);常规组治疗前后外周血中上述细胞比例均无明显变化。在细胞回输过程中,仅1例次出现发热,体温37.8 ℃,未经处理恢复正常。所有患儿的血生化、肝肾功能及心电图在细胞治疗后与常规组比较,均差异无统计学意义。结论 Ag-DC-CIK细胞治疗晚期RB安全、有效。
Abstract
Objective To evaluate the clinical efficacy and safety of co-cultured autologous tumor antigen-loaded dendritic cells (DC) and cytokine-induced killer cells (CIK) (Ag-DC-CIK) combined with routine therapy in the treatment of advanced retinoblastoma (RB). Methods 26 patients suffering from RB who were diagnosed as advanced RB in the General Hospital of the Chinese People’s Armed Police Forces between December 2011 and December 2014. 13 patients received Ag-DC-CIK combined with routine treatment (combination group). The other patients received routine therapy (routine group). Results The combination group totally received 67 cycles (134 times) Ag-DC-CIK therapy. At the end of the follow-up, all patients in combination group who suffered D got the opportunity of reserving eyes; 2 out of 4 patients who lost the opportunity of operation had surgery eventually. All the group D patients of routine group underwent enucleation. 1 out of 4 patients who lost the opportunity of operation had surgery eventually. CD3+, CD4+ , CD4+/CD8+ and CD3+ CD56+ proportion in the combination group was higher than in another group, CD8+ proportion in the combination group was lower than in the routine group, and the difference was statistically significant (P<0.05). Only one patient had a fever (37.8 ℃) during the therapy, and could return to normal itself. Both groups of patients’ hepatorenal function, blood biochemistry and ECG had no statistically significant differences. Conclusions Ag-DC-CIK combined with routine therapy in the treatment of advanced RB is efficient and safe.
关键词
细胞因子诱导的杀伤细胞 /
树突状细胞 /
视网膜母细胞瘤 /
化疗 /
安全性
Key words
cytokine-induced killer cells /
dendritic cells /
retinoblastoma /
chemotherapy /
safety
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Zhan H L, Gao X, Pu X Y, et al. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma [J]. Chin Med J (Engl), 2012, 125(21):3771-3777.
[2] Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients [J]. Cancer Immunol Immunother, 2013, 62(1): 65-73.
[3] 苏 毅,易 海,范方毅,等.荷载自体白血病抗原的DC-CIK细胞预防急性髓细胞性白血病自体造血干细胞移植后复发的临床研究[J].中国输血杂志,2010,23(12):1024-1028.
[4] Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification [J]. Ophthalmol Clin North Am, 2005, 18(1): 41-53.
[5] Chen R, Deng X, Wu H, et al. Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis [J]. Int Immunopharmacol, 2014, 22(2): 451-464.
[6] Jkel C E,Hauser S,Rogenhofer S,et al.Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma [J]. Clin Dev Immunol, 2012,2012: 1-7.
[7] Wang Y F, Kunda P E, Lin J W, et al. Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells [J]. Oncol Rep, 2013, 29(5): 1841-1850.
[8] Liu Q, Wang Y, Wang H, et al. Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis [J]. J Cancer Res Clin Oncol, 2013, 139(8): 1357-1372.
[9] 刘清池,张慧敏,张玉娜,等. DC-CIK细胞清除微小残留白血病的临床研究[J].中国肿瘤生物治疗杂志,2013,20(4): 398-403.
[10] Ren J, Di L, Song G, et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences [J]. Clin Transl Oncol, 2013, 15(10): 780-788.
[11] 张俊萍,毛光华,史天良,等.DC-CIK联合化疗治疗晚期非小细胞肺癌的临床疗效[J].中国肿瘤生物治疗杂志,2011,18(4): 424-429.
[12] 龚 奕,陈幸华,张 曦,等.急性髓细胞白血病患者DC-CIK治疗后T细胞亚群动态变化的临床观察[J].2012,25(2):112-114.
基金
首都特色临床应用研究(Z121107001012055)
PDF(903 KB)
